Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Non-Current Liabilities: 2019-2025

Historic Other Non-Current Liabilities for Fulcrum Therapeutics (FULC) over the last 6 years, with Sep 2025 value amounting to $197,000.

  • Fulcrum Therapeutics' Other Non-Current Liabilities changed negligibly% to $197,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $197,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $197,000 for FY2024, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Other Non-Current Liabilities of $197,000 as of Q3 2025, which was down 0.00% from $197,000 recorded in Q2 2025.
  • Fulcrum Therapeutics' Other Non-Current Liabilities' 5-year high stood at $447,000 during Q2 2023, with a 5-year trough of $197,000 in Q2 2022.
  • For the 3-year period, Fulcrum Therapeutics' Other Non-Current Liabilities averaged around $230,909, with its median value being $197,000 (2025).
  • As far as peak fluctuations go, Fulcrum Therapeutics' Other Non-Current Liabilities skyrocketed by 126.90% in 2023, and later plummeted by 55.93% in 2024.
  • Over the past 4 years, Fulcrum Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $197,000 in 2022, then remained steady at $197,000 in 2023, then remained steady at $197,000 in 2024, then remained steady at $197,000 in 2025.
  • Its Other Non-Current Liabilities was $197,000 in Q3 2025, compared to $197,000 in Q2 2025 and $197,000 in Q1 2025.